Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

MOLECULAR EXPRESS, INC

UEI: R1JMHFESEKD5CAGE: 337D8

MOLECULAR EXPRESS, INC is a federal contractor, registered under UEI R1JMHFESEKD5 and CAGE code 337D8. It has been awarded $35,114,556 in federal contracts. Primary work spans Unknown NAICS, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services, Department Of Defense, and Department Of Health And Human Services (hhs).

Contact Information

Registration and classification details

Registration

UEI Code

R1JMHFESEKD5

CAGE Code

337D8

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationMinority-Owned BusinessAsian-Pacific American Owned

NAICS Codes

541713Research and Development in Nanotechnology
541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Molecular Express, Inc. specializes in the design and formulation of novel immunotherapeutic agents and co-adjuvant systems for infectious disease applications, with a focus on TLR7 agonists, HIV immunogens, and vaccine delivery platforms. The company’s core technical expertise lies in molecular for...

Molecular Express, Inc. specializes in the design and formulation of novel immunotherapeutic agents and co-adjuvant systems for infectious disease applications, with a focus on TLR7 agonists, HIV immunogens, and vaccine delivery platforms. The company’s core technical expertise lies in molecular formulation science, immunological adjuvant development, and preclinical biopharmaceutical engineering, particularly in optimizing antigen stability, immune activation profiles, and formulation bioavailability. Their work demonstrates deep proficiency in structure-function analysis of vaccine candidates and the engineering of precision-delivery systems tailored for dendritic cell targeting and sustained immune response modulation. Differentiators include a strong emphasis on translational biotechnology—bridging molecular design with functional immunological outcomes—without reliance on nanotechnology or biotech platforms outside their defined scope. The company maintains a consistent, focused relationship with the Department of Health and Human Services, delivering research and development services aligned with public health priorities in vaccine innovation and infectious disease countermeasures. Their engagements with HHS center on advanced immunogen design and formulation science, indicating a trusted partnership in advancing next-generation prophylactic and therapeutic candidates for high-priority pathogens. Molecular Express operates primarily within NAICS 541714 and 541715, which reflect specialized biotechnology R&D and broader life sciences research excluding nanotechnology. Their market positioning is that of a niche biopharmaceutical R&D firm focused on immunomodulatory formulation science, serving government-funded programs requiring rapid prototyping and preclinical validation of novel vaccine architectures. As a small business structured as a 2L entity based in Rancho Dominguez, California, Molecular Express operates without federal certifications but maintains a focused presence in the U.S. government’s biomedical R&D ecosystem, positioning itself as a responsive, technically agile partner for HHS-led initiatives in vaccine development and immunological innovation.

Key Performance Metrics

Awards Count

45

All time

Active

2

Currently performing

Completed

43

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by Agency Over Time
Awards by Place of Performance

Compete with MOLECULAR EXPRESS, INC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for MOLECULAR EXPRESS, INC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in MOLECULAR EXPRESS, INC's top NAICS codes and agencies

NAICS: 541715
New
Federal
U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911PT26SC001
The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) has issued solicitation W911PT26SC001, a Commercial Solutions Opening (CSO) authorized under the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70. This competitive solicitation is open until September 30, 2027, and is designed to acquire innovative commercial products, technologies, and services to modernize the Army's Organic Industrial Base. The scope focuses on integrating manufacturing resources, linking legacy analogue systems with digital systems, and expanding modeling and simulation to enhance the delivery of materiel solutions. The CSO targets both traditional and non-traditional business entities, including small businesses and foreign-owned firms, provided they maintain an active System for Award Management (SAM) profile and a Unique Entity ID. The acquisition process follows a multi-phased approach consisting of a written solution brief, an optional presentation or pitch, and a final Request for Commercial Solution Proposal (CSP). Evaluation is based on responsiveness, technical merit, uniqueness, and price reasonableness. Successful responses may result in fixed-price contracts awarded under FAR Part 12 Commercial Item Procedures. Current Areas of Interest (AoIs) include advanced cannon technology, electrical infrastructure improvements at Building 120, chromium facility conversion, automated manufacturing for minor components, automated cooling tower treatments, advanced CNC vertical turning lathes, and advanced tooling for radial forging. Performance is primarily located at Watervliet Arsenal and Benet Laboratories, with a general period of performance not to exceed 12 months unless otherwise specified.
W6QK Acc Wva

POSTED

about 18 hours ago

DEADLINE

in 11 months
View Details
NAICS: 332812
New
Federal
Area of Interest (AoI) – Metal Cleaning and Finishing Services
Solicitation # W911KF25SC002-AoI0016
The Army Contracting Command Anniston Army Depot is seeking innovative commercial solutions for depot-level metal cleaning, surface preparation, and finishing services for combat vehicle components. This requirement, issued under solicitation W911KF25SC002-AoI0016, encompasses chemical stripping, alkaline immersion cleaning, and abrasive media cleaning to remove paint, corrosion, scale, and carbon. The scope includes a wide array of plating and coating processes such as anodizing, chromate conversion, black oxide, electroless nickel, hard chrome, zinc, tin, copper, and phosphate. The government anticipates utilizing a Multiple Award Task Order Contract structure to ensure technical redundancy and coverage. Key performance requirements include a strict seven-working-day turnaround time and the contractor's responsibility for the secure pick-up and delivery of parts to and from the depot in Alabama. Offerors must demonstrate significant facility capabilities, including specific tank and oven dimensions, crane clearances, and the capacity to handle high-volume part streams of varying sizes. A rigorous quality assurance approach is mandatory, requiring the ability to perform various ASTM and MIL-SPEC tests, such as salt spray, adhesion, and hydrogen embrittlement, either in-house or through certified laboratories. Evaluation will be based on technical feasibility, the safety and efficiency of cleaning methods, innovation in eco-friendly processing, and the robustness of quality control systems. Additionally, the government will assess the offeror's track record with hazardous material management and compliance with environmental regulations. Interested parties must submit a written Solution Brief by October 28, 2026, including a Rough Order of Magnitude or unit pricing structure for evaluation.
Department Of Defense

POSTED

about 18 hours ago

DEADLINE

in 8 days
View Details
NAICS: 541715
New
Grant
Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
Solicitation # RFA-DC-28-002
Solicitation RFA-DC-28-002 is a Notice of Funding Opportunity from the National Institutes of Health, specifically the National Institute on Deafness and Other Communication Disorders, to establish a Coordinating Center for the NIDCD National Human Ear Resource Network. This collaborative network provides human inner and middle ear tissues to researchers for basic and clinical studies aimed at advancing the treatment of auditory and vestibular disorders. The Coordinating Center is responsible for maintaining network cohesiveness through the planning of workshops, symposia, and regular meetings, providing updates to laboratories, and managing communication with the public and scientific community regarding tissue donation. The maximum project period is five years, with a budget limit of 200,000 dollars in direct costs per year. Applicants, including for-profit organizations and small businesses, must maintain active registrations in SAM, eRA Commons, and Grants.gov. Proposals are evaluated based on the significance of the proposed center and the qualifications of the investigators, with additional reviews for human subject protections, inclusion policies, and the use of vertebrate animals. Key requirements include a structured Data Management and Sharing Plan and adherence to cybersecurity guidelines, including a 48-hour incident reporting window. The application process is entirely electronic and requires several standard PHS and SF424 forms, with a response deadline of March 5, 2027.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 4 months
View Details
NAICS: 541715
New
Grant
National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
Solicitation # RFA-DC-28-001
Solicitation RFA-DC-28-001 is a Notice of Funding Opportunity issued by the National Institutes of Health under the Department of Health and Human Services to support the NIDCD National Human Ear Resource Network. The objective is to maintain a collaborative network of laboratories that serve as a national technological resource, providing human inner and middle ear tissues to researchers for basic and clinical studies to advance the treatment of auditory and vestibular disorders. The scope of work includes processing human temporal bones from the National Hearing and Balance Organ Donor Program, uploading images and medical data to EarBase, sharing gene-expression data via the gEAR repository, and providing technical instruction to increase the number of skilled researchers in the field. The NIDCD intends to commit 3.6 million dollars in FY 2028 to fund up to six awards, with a maximum project period of five years. Individual awards are limited to 450,000 dollars in direct costs per year, with an additional 150,000 dollars available for specific subawards. Applications are due on March 05, 2027, and November 01, 2027, with staggered start dates ranging from July 2027 to July 2028. Evaluation is based on the experience of the investigators, the adequacy of the institutional environment, and the protection of human subjects. Applicants must maintain active SAM registration and a Unique Entity Identifier, and they must provide a Data Management and Sharing Plan and a Material Transfer Agreement. Compliance with the Cybersecurity Act of 2015 is required, including the development of an incident response plan and notification of cybersecurity incidents within 48 hours of discovery.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in about 1 year
View Details
NAICS: 541714
New
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
View Details